Apollo Hospitals Q4 Results Review - Inline Ebitda; Hospital Margins To Improve: Prabhudas Lilladher

Prabhudas Lilladher Report

Apollo Hospitals Enterprise Ltd. reported consolidated Ebitda of Rs 6.4 billion (up 31% YoY), in line with our estimates. Adjusted for 24x7 losses and ESOP cost (~Rs 1.5 billion), Ebitda was Rs 7.9 billion, up 12% YoY.

The recent stake sale in HealthCo to Advent and merger with Keimed are a positive step and will lead to an integrated pharmacy distribution business complemented by the fast-growing omni-channel digital health business.

Scale-up in Apollo HealthCo has been on track with likely breakeven in Ebitda of digital business over the next six-eight quarters. Further, the management guidance of Rs 17.5-20 billion Ebitda of the merged entity by FY27, provides comfort.

Our FY25E and FY26E Ebitda estimates broadly remain unchanged. Overall we estimate 18% Ebitda compound annual growth rate over FY24-26E (ex 24x7 losses).

We maintain ‘Buy’ rating with a target price of Rs 7,050/share. We ascribe 25 times enterprise value/Ebitda multiple to hospital and offline pharmacy, and assign one time sales to the 24/7 business.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.